/PRNewswire/ Newpath Partners, a venture firm dedicated to life science investments, today announced the launch of Fund II. With its second fund in three.
/PRNewswire/ Newpath Partners, a venture firm dedicated to life science investments, today announced the launch of Fund II. With its second fund in three.
Biotech startup Exo Therapeutics aims to overcome the challenges of drugging proteins by targeting exosites, locations that modulate enzyme activity. The company has four small molecule drug candidates for cancer and inflammation, and the company plans to use the $78 million in new financing to advance them toward human testing.